The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis

Ellen Iacobaeus1*, Petra Amoudruz2*, Mikael Ström1*, Mohsen Khademi1, Lou Brundin1, Jan Hillert3, Ingrid Kockum1, Vivianne Malmström2, Tomas Olsson1, Emma Tham4, Fredrik Piehl1

1 Department of Clinical Neuroscience, Neuroimmunology Unit, Karolinska Institute Solna, Center for Molecular Medicine, Stockholm, Sweden, 2 Department of Medicine, Rheumatology Unit, Karolinska Institute Solna, Center for Molecular Medicine, Stockholm, Sweden, 3 Department of Clinical Neuroscience, The Multiple Sclerosis Research Group, Karolinska Institute Solna, Center for Molecular Medicine, Stockholm, Sweden, 4 Department of Clinical Genetics, L5:03, Karolinska University Hospital, Solna, Sweden

Abstract

Background: Most patients with relapsing-remitting multiple sclerosis (RRMS) eventually enter a secondary progressive (SPMS) phase, characterized by increasing neurological disability. The mechanisms underlying transition to SPMS are unknown and effective treatments and biomarkers are lacking. Vascular endothelial growth factor-A (VEGF-A) is an angiogenic factor with neuroprotective effects that has been associated with neurodegenerative diseases. SPMS has a prominent neurodegenerative facet and we investigated a possible role for VEGF-A during transition from RRMS to SPMS.

Methodology/Principal Findings: VEGF-A mRNA expression in peripheral blood mononuclear (PBMC) and cerebrospinal fluid (CSF) cells from RRMS (n = 128), SPMS (n = 55) and controls (n = 116) were analyzed using real time PCR. We demonstrate reduced expression of VEGF-A mRNA in MS CSF cells compared to controls (p<0.001) irrespective of disease course and expression levels are restored by natalizumab treatment (p<0.001). VEGF-A was primarily expressed in monocytes and our CSF findings in part may be explained by effects on relative monocyte proportions. However, VEGF-A mRNA expression was also down regulated in the peripheral compartment of SPMS (p<0.001), despite unchanged monocyte counts, demonstrating a particular phenotype differentiating SPMS from RRMS and controls. A possible association of allelic variability in the VEGF-A gene to risk of MS was also studied by genotyping for six single nucleotide polymorphisms (SNPs) in MS (n = 1114) and controls (n = 1234), which, however, did not demonstrate any significant association between VEGF-A alleles and risk of MS.

Conclusions/Significance: Expression of VEGF-A in CSF cells is reduced in MS patients compared to controls irrespective of disease course. In addition, SPMS patients display reduced VEGF-A mRNA expression in PBMC, which distinguish them from RRMS and controls. This indicates a possible role for VEGF-A in the mechanisms regulating transition to SPMS. Decreased levels of PBMC VEGF-A mRNA expression should be further evaluated as a biomarker for SPMS.

Introduction

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). A majority of patients initially display a relapsing-remitting disease course (RRMS), characterized by inflammatory demyelinating attacks, axonal injury and varying degree of repair [1]. However, most RRMS patients with time enter a secondary progressive phase (SPMS), with failure of repair mechanisms leading to gradual neurodegeneration and a continuous accumulation of disability [1]. The strongest predictive factors favoring an earlier transition to a progressive disease course are efferent symptoms and lack of complete remission of the onset bout [2]. The neurodegenerative component in progressive MS is more prominent and disease
modulatory treatments, even those shown to be effective in breakthrough RRMS disease, have only limited effects in SPMS [3,4,5]. Very little is known about the mechanisms underlying the transition to progressive MS disease and the diagnosis of a progressive disease course is made solely on clinical grounds, since reliable supporting laboratory or neuroradiological tests are lacking [6]. In clinical practice it is often difficult to determine when the progressive disease starts until it has already been going on for a longer time, which makes it complicated to use as an outcome in clinical trials and also poses a clinical problem for treatment decisions.

A number of potential biomarkers for monitoring of MS disease course, response to therapies and prediction of disability have been studied, some of them with promising results [7,8]. However, there is a scarcity of candidates evaluated as biomarkers for SPMS, although a recent study demonstrated that levels of complement factor H is elevated in SPMS compared to RRMS [9]. Vascular endothelial growth factor A (VEGF-A) is an angiogenic and pro-inflammatory factor with neuroprotective effects on neuronal and glial cells that also stimulates proliferation and survival of neural stem cells [10,11]. Studies on the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) have suggested a role for VEGF-A in the pathogenesis of these diseases and a genetic association between VEGF-A variants and these diseases has been demonstrated [12,13,14,15,16,17,18]. Results from a few smaller studies have also indicated a role for VEGF-A in MS [19,20,21,22,23]. We previously observed decreased levels of VEGF-A in cerebrospinal fluid (CSF) cells from a small group of MS patients compared to controls [22]. The objective of this study was to determine VEGF-A expression profiles in CSF and peripheral blood in a large cohort of well characterized MS patients and relate this to different disease measures. In addition, we have investigated if genetic variability in the VEGF-A gene is associated to risk of MS.

Methods
Ethics Statement
The study was approved by the regional ethical committee, “Regionala etikprövningsnämnden i Stockholm, EPN” and written informed consent was obtained from all patients.

Patients
All CSF- and peripheral blood mononuclear cells (PBMC) samples were obtained from our in-house biobank containing samples collected, during routine neurological diagnostic work up or during clinical follow-up, from 2001 to 2009. Samples from natalizumab treated patients were collected before and after one year of treatment for study purposes. Demographic data of the patients included in the expression studies are described in Table S1. Two patient cohorts were used for VEGF-A expression analysis; study group A composed of RRMS (n = 63), SPMS (n = 35) and controls with other non-inflammatory neurological diseases (OND) (n = 68), and study group B used for replication with RRMS (n = 65), SPMS (n = 20) and OND (n = 48). All MS patients fulfilled the McDonald criteria [24]. Classification and scoring of MS patients was assessed by a trained neurologist. For RRMS, a relapse was defined as an increase with ≥1 point on the expanded disability status scale (EDSS), with duration of at least one week before sampling, where systemic infection had been ruled out. Remission was defined as a stable clinical status >3 months prior to sampling. SPMS was defined as an initial relapsing-remitting disease course followed by more than 12 months of continuous worsening of neurological function (≥0.5 EDSS point) not explained by relapses. At time of sampling, 14 RRMS patients were on immunomodulatory treatment including IFN-β1a (n = 0), IFN-β1b (n = 3), glatiramer acetate (n = 2) and intravenous immunoglobulins (n = 1), and 2 OND patients were on low doses of oral corticosteroids. Magnetic resonance imaging (MRI) data obtained within 2 months of sampling was available in 80 cases. Routine MRI examinations and determination of oligoclonal bands and IgG index in CSF and serum were performed as described previously [25]. The OND control groups included patients with diagnoses listed in Table S2.

Sample preparation and mRNA expression analysis
CSF cells were collected and processed as previously described [26]. Peripheral blood was collected in sodium citrate-containing cell preparation tubes (Vacutainer CPT; BD Biosciences, San Jose, California, USA) and EDTA tubes. PBMC were separated by density gradient centrifugation and cells from the interphase were collected and washed twice with Dulbecco’s PBS. Cell pellets were frozen on dry ice and stored at −80°C until analysis. Total RNA was extracted and reverse transcribed as previously described [26]. Two RT-PCR expression assays were used; The SYBR-Green-based protocol was used for analysis on study group A and the TaqMan gene expression assay was used for study group B. A BioRad iQ5 iCycler Detection System (BioRad Laboratories, Ltd) was used for both protocols. A three-step PCR protocol (95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, 60°C for 30 sec and 72°C for 30 sec) with SYBR-Green-based primers (sequences available upon request) and a two-step PCR protocol (95°C for 10 min, followed by 40 cycles of 95°C for 15 sec. and 60°C for 1 min), with FAM fluorophore was used for the TaqMan gene expression assay (ordered online from https://products.appliedbiosystems.com). The TaqMan gene expression assay ID for different targets were: GAPDH (Assay ID: Hs99999905_ml and VEGF-A (Assay ID: Hs00173626_ml. Relative quantification of mRNA was performed using the standard curve method using GAPDH as endogenous control. PCR efficiencies ≥90% were accepted. Analytical sensitivity performance characteristics were determined using ten-fold serial dilutions of pooled cDNA from twenty cases and controls as standard curve, and GAPDH as an internal endogenous control for the housekeeping gene. Intra-run replicates of serially diluted cDNA over the linear range of the assay demonstrated minimal variation in cycle threshold (Ct) values with a variation of <0.2 Ct, approximately corresponding to <5% variability in absolute levels.

Flow cytometry
PBMC were isolated (as described above) from freshly collected blood samples obtained during clinical follow-up from five treatment naive RRMS patients (2 females, 3 males; mean age 35) and nine RRMS patients treated with 2–24 infusions of natalizumab (4 females, 5 males; mean age 35 years). Cell populations sorted from PBMC included pure CD3+CD4+ (helper T cells), CD3+CD4+ (mainly cytotoxic T cells), CD19+ (B cells) and CD14+ (monocytes) in the treatment naive MS patient group and CD3+CD4+ (helper T cells), CD3+CD8+ (cytotoxic T cells), CD3+CD4+CD25+ (regulatory T cells; Treg), CD3+CD304+ (plasmacytoid dendritic cells; pDC) and monocyte gated cell populations in the natalizumab treated group. Cell populations were sorted from PBMC on a MoFlo high-speed cell sorter (DakoCytomation, Glostrup, Denmark) after staining with fluorescently labeled Abs from BD Biosciences, (San Jose, CA) and Miltenyi Biotec GmbH (Surrey, UK). After centrifugation, the cell pellets were lysed and prepared for RNA preparation and cDNA
synthesis, with subsequent real-time PCR analysis using the SYBR-Green based protocol as described above.

Genetic association study

A genetic association study was performed on 1114 Swedish patients with a MS diagnosis according to either Poser [27] or McDonald [24] (73% females, 27% males; mean age at sampling 53 years, IQR 22–91 years). The control group consisted of 1234 healthy blood donors (63% female and 37% male; mean age at sampling 47 years, IQR 21–76 years). Blood was sampled between 1987 and 2004 and genomic DNA was extracted from whole blood using standard procedures. Genotyping was performed with TaqMan SNP genotyping assay (Applied Biosystems) according to the manufacturer’s instructions with 225 nM primer, 50 nM probe and 1 ng/μl genomic DNA in a total reaction volume of 5 μl. Further details are available upon request. Six SNPs tagging haplotype blocks across the entire VEGF-A gene on chromosome 6p21.3 were selected with request. Six SNPs tagging haplotype blocks across the entire analysis for risk of MS and single SNPs and haplotypes in VEGF-A were analyzed in CSF or PBMC or CSF cells (Figure S1). Analyses were carried out in A was performed with R 2.8.0 using the package SNPassoc [28] and with Haplovew 4.0. Power analysis was performed using genetic Power Calculator with a estimated prevalence for MS of 0.001 and a multiplicative model and type 1 error = 0.05 for allele test [29].

Results

VEGF-A mRNA expression in PBMC and CSF cells

The relative expression of VEGF-A mRNA in CSF cells was drastically reduced both in RRMS and SPMS compared to controls as determined by SYBR-Green quantitative PCR in a first set of patients (study group A). Thus, RRMS displayed a three-fold and SPMS an eight-fold reduction of VEGF-A mRNA expression compared to OND controls in CSF cells (Figure 1A). In contrast, VEGF-A mRNA levels in PBMC were similar in RRMS and controls, but significantly reduced in SPMS (Figure 1B). No significant difference between RRMS in relapse and remission was found in CSF cells or PBMC. Both the findings of a dawn regulation of VEGF-A expression in CSF cells irrespective of disease course and the down regulation in PBMC solely in SPMS were corroborated in a separate set of patients (study group B) using a probe-based TaqMan PCR protocol (Figure S1A, B). In addition, there was a trend towards higher levels of VEGF-A expression in PBMC from RRMS sampled during a relapse as compared to patients in remission (Figure S1B).

Expression of VEGF-A in CSF cells or PBMC was not correlated to any measures of disease severity (EDSS, MSSS, disease duration), nor did the expression differ between groups with or without more than nine T2 MRI lesions, or oligoclonal bands and/or increased IgG-index (data not shown). The expression level of VEGF-A mRNA in CSF cells and PBMC was positively correlated in the SPMS group in study group A ($R^2 = 0.17, p-value: 0.01612$) and with borderline significance in study group B ($R^2 = 0.19, p-value 0.059$). No significant correlation between VEGF-A mRNA expression in CSF cells and PBMC was observed in RRMS or in the control groups. In addition, neither gender nor age correlated with VEGF-A expression in PBMC or CSF cells (Figure S2).

Table 1. Association analysis for risk of MS and single SNPs and haplotypes in VEGF-A.

| SNP #  | Mb       | Position | Genotype frequencies | Alleles | MAF | % GT | HWE P-value | P-value |
|-------|----------|----------|----------------------|---------|-----|------|-------------|---------|
|       | MB       | Controls | MS                   | majorminor |     |      |             |         |
| Rs303606a | 43,843,127 | 712/424/71 | 616/337/71 | G:T | 70.0 | 76.6 | 96.5 | 91.3 | 0.0264 | 0.4704 | 0.0112 | 0.3894 |
| Rs699947b | 43,844,367 | 332/596/311 | 274/493/255 | A:C | 47.8 | 51.0 | 98.3 | 91.2 | 0.0740 | 0.1922 | 0.2606 | 0.9986 |
| Rs1570360c | 43,845,808 | 570/495/125 | 413/375/110 | G:A | 67.6 | 67.6 | 91.4 | 80.1 | 0.0089 | 0.2525 | 0.0837 | 0.4114 |
| Rs25648 | 43,846,955 | 567/280/25 | 682/290/28 | C:T | 82.3 | 82.0 | 82.3 | 89.2 | 0.2453 | 0.1864 | 0.7407 | 0.3346 |
| Rs3025030 | 43,858,565 | 866/336/28 | 736/269/32 | G:C | 84.5 | 84.1 | 98.4 | 92.3 | 0.6415 | 0.5941 | 0.2486 | 0.4075 |
| Rs10434 | 43,861,190 | 342/612/278 | 279/511/249 | G:A | 56.2 | 52.1 | 98.0 | 92.7 | 0.7083 | 0.9090 | 0.6196 | 0.7142 |

No genetic association was found between SNPs in the VEGF-A gene and overall risk for MS in 1114 MS (n = 1114) healthy controls (n = 1234).

aVEGF-A exon 1 starts at position 43,845,931. All positions according to NCBI SNP database.

bNo allele frequency data available in HapMap or dbSNP.
cNo allele frequency data available in HapMap or dbSNP.

dAlso denoted $2578C/A$. The AA genotype has lower VEGF-A levels [45,46], increased risk of Alzheimer’s disease [18] and increased risk of Alzheimer’s disease [18].

eAlso denoted $-1154G/A$. A-allele and AA-genotype lowers VEGF-A levels [45,46].
Monocytes as the main cellular source of VEGF-A mRNA

In sorted PBMC populations from treatment-naïve MS patients, expression of VEGF-A mRNA was found mainly in CD14+ monocytes (Figure 2A). In a prior study we detected expression of VEGF-A in mononuclear cell infiltrates in rats with experimental autoimmune encephalomyelitis (EAE) [22], suggesting that VEGF-A could potentially be expressed in T regulatory cells and/or myelin-specific autoreactive T cells that are enriched in the CNS of MS patients. We therefore took advantage of the therapeutic effect of natalizumab, which blocks the transmigration of lymphocytes across the blood-brain barrier resulting in peripheral sequestration of encephalitogenic T cells [30]. VEGF-A mRNA levels were determined in sorted PBMC from nine patients treated with natalizumab. Again, levels of VEGF-A were highest in monocytes and low or undetectable in the other analyzed cell populations (Figure 2B). Thus, in PBMC, monocytes constitute the major source of expression of VEGF-A, with some expression also in B cells and CD8+ T cells.

In order to exclude that reduced VEGF-A expression levels in PBMC from SPMS patients could be explained by difference in cellular composition, absolute and relative peripheral blood monocyte numbers were determined as part of a complete peripheral blood count in RRMS (n = 53), SPMS (n = 19), and controls (n = 58). This analysis did not reveal any discernible differences in the absolute or relative number of peripheral blood monocytes between the different groups (Table 2).

Effect of natalizumab on VEGF-A mRNA expression

In order to test if immunomodulatory treatment could alter the expression of VEGF-A, we studied the effect of natalizumab treatment in a set of RRMS patients. As monocytes express the highest levels of VEGF-A, we also estimated the relative proportion of monocytes by measuring the expression of the monocyte cell marker CD14. VEGF-A and CD14 mRNA in CSF cells and PBMC were determined in 19 RRMS patients (10 females, 9 males, mean age 40 years, IQR 33–49 years) prior to initiation of natalizumab and again after 12 months of treatment. There was a robust increase in CSF cell VEGF-A expression and a more moderate increase of CD14 mRNA expression in CSF cells, but no change in PBMC (Figure 3), suggesting both an effect on cellular CSF composition and a relative increased in VEGF-A expression.

Figure 1. Box-whisker plot of VEGF-A mRNA expression in CSF cells and peripheral blood mononuclear cells (PBMC). Relative VEGF-A mRNA expression is reduced in CSF cells (A) in RRMS (n = 34) and SPMS (n = 32) compared to controls (OND; n = 47), and in PBMC (B) from SPMS (n = 35) compared to RRMS (n = 63) and OND (n = 68). No significant difference between RRMS in relapse and remission is seen in CSF cells (relapse n = 17, remission, n = 17) or PBMC (relapse n = 31, remission n = 32). *p<0.05; **p<0.01; ***p<0.001. All values were normalized to the median OND value in CSF cells and PBMC, respectively.

doi:10.1371/journal.pone.0019138.g001

Figure 2. Box-whisker plot of VEGF-A mRNA expression in sorted peripheral blood mononuclear cell (PBMC) populations. Relative VEGF-A mRNA expression in sorted PBMC populations from (A) untreated RRMS (n = 5) and (B) RRMS treated with natalizumab (n = 9) demonstrate the highest expression of VEGF-A in the monocyte population in both groups. Monocytes were defined either as CD14+ (A) or by gating of forward and side scatter (B). pDC = plasmacytoid CD3-CD304+ cells, Treg = CD3+CD4+CD25+ cells.

doi:10.1371/journal.pone.0019138.g002
VEGF-A gene variants were not associated with risk of MS

The VEGF-A gene was genotyped with six SNPs in 1114 MS patients and 1234 controls covering haplotype blocks across the gene and promoter sequence. This study had 80% power to detect an odds ratio of 1.5 in the allelic test. No significant association between single SNP alleles or genotypes or VEGF-A haplotypes and overall risk for MS was found (Table 1). There were no gender differences in association of genotypes to MS. Furthermore, there was no correlation between VEGF-A alleles and VEGF-A expression in PBMC in a subset of MS patients (n = 85) and OND controls (n = 48). The sample size and the lack of detailed and updated phenotypic information on disease course excluded the possibility to perform association to risk of progressive MS.

Discussion

We here reproduce, in a large cohort, our previous findings that VEGF-A mRNA expression is reduced in CSF cells of MS patients [22]. However, the main novel finding of the present study is that SPMS patients are characterized by a prominent decrease of VEGF-A mRNA expression in PBMC compared to both RRMS and controls, who display comparable levels of VEGF-A expression. We could not demonstrate any significant correlation to age or a number of clinical or paraclinical parameters, such as EDSS, MSSS, disease duration or number of T2 MRI lesions, which is in agreement with a previous study [21]. These results suggest that down regulation of VEGF-A mRNA expression in PBMC reflects an underlying disease mechanisms that operates specifically in progressive MS. This finding is of interest in the context of emerging evidence that connects dysregulation of VEGF-A to neurodegenerative processes [31]. Thus, VEGF-A protects neurons from environmental stress and apoptosis and can directly stimulate neurogenesis and axonal regeneration [10,31]. Targeting of the hypoxia-response element in the VEGF gene leads

Table 2. Absolute and relative number of peripheral blood (PB) monocytes.

|          | RRMS | SPMS | OND | p-value |
|----------|------|------|-----|---------|
| Absolute no. of PB monocytes | 0.4  | 0.4  | 0.3  | ns      |
| median (IQR) 10⁷/L    | (0.3–0.5) | (0.3–0.4) | (0.3–0.4) |         |
| Relative no. of PB monocytes | 0.25 | 0.24 | 0.21 | ns      |
| median (IQR) 10⁷/L    | (0.17–0.3) | (0.18–0.53) | (0.40–0.25) |         |

No discernible difference in the absolute or relative number of peripheral blood monocytes, as determined by peripheral blood count, are evident between RRMS, SPMS and OND.

doi:10.1371/journal.pone.0019138.t002

Figure 3. Box-whisker plot demonstrating the VEGF-A and CD14 mRNA expression in RRMS before and after natalizumab treatment. The effect of treatment on expression of VEGF-A in PBMC and CSF cells was studied in 19 RRMS patients prior to initiation of natalizumab and again after 12 months of treatment. Expression of CD14 was used as a marker of monocytes. There is a robust increase in CSF cell VEGF-A mRNA expression, (A) and a more moderate increase of CD14, (C) mRNA expression in CSF cells sampled after initiation of natalizumab treatment. In contrast, expression of VEGF-A and CD14 is not changed in PBMC after treatment with natalizumab (B, D). *p<0.05; **p<0.01; ***p<0.001.

doi:10.1371/journal.pone.0019138.g003
to degeneration of motorneurons and intracerebroventricular delivery of VEGF-A in a rat model of ALS delays onset of motorneuron degeneration and prolongs survival [12,14]. The sensitivity of motorneurons to dysregulation of VEGF-A is interesting in light of the recent demonstration of a major loss of spinal motorneurons also in MS [32]. Of note, Seabrook et al demonstrated decreased levels of VEGF-A protein in rat spinal cord tissue during EAE relapse and a reduced expression in neurons upon immunohistochemistry [33]. Other studies on RRMS have reported increased VEGF-A mRNA expression in smaller groups of MS patients during relapse compared to remission and/or controls in peripheral blood and CSF [21,23]. In addition, Su et al showed that the higher serum levels of VEGF-A decreased within one month from relapse onset and tended to be lower than healthy controls during remission. An increase of VEGF-A in the initial phases of relapse is compatible with its role as a pro-inflammatory factor that attracts monocytes and lymphocytes, upregulates immunomodulatory adhesion molecules, stimulates secretion of proinflammatory cytokines, and increases blood-brain barrier permeability [22,34]. We observed a tendency towards higher VEGF-A mRNA levels in relapse compared to remission only in one of the studied cohorts. This discrepancy may be related to the timing of sampling in relation to onset of relapse symptoms or the occurrence of subclinical disease activity in the remission group. It is known that the net effect of VEGF-A can vary depending on the target tissue, the timing and the concentration [35]. Neuroprotection of the ischemic brain is critically dependent on proper dosage and may be compromised by angiogenesis, which may explain why VEGF-A in some studies show increased expression [19,21,36] and correlate to exacerbation of disease in EAE [19,37], while others report decreased expression [22,38]. We measured VEGF-A protein levels with ELISA in a small subset of patients for which plasma samples were available, revealing a non significant trend towards decreased levels in SPMS patients compared to RRMS and controls (data not included). Replication in larger materials is therefore needed to demonstrate if VEGF-A expression differences also are translated into changes in protein levels in peripheral blood.

The neurodegenerative disorders ALS and AD disease have been associated with a genetic variation in the VEGF-A gene (−2578AA; rs699947) associated with reduced VEGF-A levels [17,18]. We were here unable to demonstrate any haplotype dependent association to overall risk of MS. However, the genetic contribution of the described SNP is modest, since meta-analyses suggest an overall 1.14–1.19 fold increased risk of ALS or AD in subjects carrying the −2578AA genotype [17,18] and relative risks of this magnitude are too small to be detected by our study. Larger and better characterized clinical materials are therefore needed to rule out a genetic association between VEGF-A and MS disease phenotype. The observation that monocytes are the main cellular source of VEGF-A expression raises the question if differences in the relative proportion of monocytes could affect results obtained from mixed cell populations. However, this was not the case in the periphery, since absolute and relative monocyte numbers were similar across the groups, in agreement with a previous study [39]. In contrast, the finding of reduced VEGF-A expression in CSF mononuclear cells at least in part may be explained by a relative decrease of monocyte numbers in the CSF of MS patients compared to controls [40]. We also studied the effect of natalizumab on VEGF-A expression, demonstrating a robust increase in expression by this therapy. This may be a result of a relative increase in CSF monocyte numbers, but likely also reflects a direct or indirect pharmacological effect of natalizumab on the phenotype of CSF monocytes since the treatment-induced effect on expression of CD14 was smaller.

The finding of an altered VEGF-A expression profile connected to monocytes is interesting since accumulating evidence supports a role for innate immune mechanisms in progressive MS. Thus, dendritic cells of SPMS patients secrete more proinflammatory cytokines and increased monocyte CD86 expression and IL-12 secretion is associated with transition to a progressive MS phase [41,42]. Taken together this suggests that the transition to a progressive disease course is connected with a change in underlying disease mechanisms. Indeed, the observations that clinical deterioration in SPMS generally occurs in the absence of novel inflammatory lesions and that it does not respond to traditional forms of immunomodulatory treatment support the notion that other disease mechanisms are operative [43,44].

In conclusion, we here demonstrate that expression of VEGF-A is down regulated in CSF cells irrespective of disease course, but that solely SPMS patients display down regulated VEGF-A expression in PBMC as compared to both RRMS and controls. These results extend prior observations on peripheral innate immune changes in SPMS and point towards a possible target for future disease modulatory drugs. Also, this finding may prove to be useful as a biomarker for SPMS, providing support for patient management and decisions on therapeutic interventions. Further studies are needed to address the question if dysregulated VEGF-A expression in MS is a cause or consequence of a progressive disease phenotype.

Supporting Information

Figure S1 Confirmatory analysis of VEGF-A mRNA expression in CSF cells and PBMC in a separate set of patients (study group B) composed of RRMS (n = 65), SPMS (n = 20) and controls (OND; n = 48). Expression of VEGF-A mRNA is decreased in CSF cells in RRMS and SPMS compared to OND (A). As in study group A, expression of VEGF-A mRNA is decreased in SPMS compared to both RRMS and controls (B). A non-significant trend towards higher expression of VEGF-A in PBMC is evident in RRMS sampled during a relapse (n = 14) compared to remission (n = 51). No significant differences between RRMS in relapse (n = 14) and remission (n = 51) was found in CSF cells. *p<0.05; **p<0.01; ***p<0.001. All values were normalized to the median OND value in CSF cells or PBMC. (TIF)

Figure S2 Age span in the analyzed MS and control groups (A). Patients with SPMS were older than both RRMS patients and controls with OND. No significant correlation between VEGF-A levels in CSF and age is detected in RRMS, SPMS or the pooled MS group (B). In PBMC age is not correlated to VEGF-A levels in the RRMS and SPMS groups. However, a weak correlation is evident in the pooled MS group, mostly reflecting the lower levels of VEGF-A in SPMS patients (C). Correlation was analyzed with Spearman’s rank test and line fit was determined with non-linear regression. (TIF)

Table S1 Characteristics of patients and samples included in the expression analysis. (DOC)

Table S2 Diagnoses of the patients included in the control group (OND). (DOC)
Author Contributions
Conceived and designed the experiments: EI FP TO JH. Performed the experiments: EI MS MK PA VM. Analyzed the data: EI FP ET MK.

References
1. Compton A, Coles A (2008) Multiple sclerosis. Lancet 372: 1502–1517.
2. Eriksson M, Andersson O, Runmarker B (2003) Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 9: 260–274.
3. Martellini Boneschi F, Rovaris M, Capra R, Coni G (2005) Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev, pp CD002127.
4. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98–108.
5. Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kosak T, et al. (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249: 1068–1070.
6. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907–911.
7. Sellebjerg F, Børnøen L, Khadem M, Krakauer M, Olson T, et al. (2009) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73: 2003–2010.
8. Salter J, Svenningsen A, Sundstrom P (2010) Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 16: 287–292.
9. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, et al. (2010) Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133: 1602–1614.
10. Rosemijn JM, Krum JM (2004) New roles for VEGF in nervous tissue–beyond blood vessels. Exp Neurol 187: 246–253.
11. Zacchigna S, Lambrechts D, Carmeliet P (2008) Neurovascular signalling in neurodegeneration. Nat Rev Neurosci 9: 169–181.
12. Oosthuyse B, Moons L, Storkelaeb E, Beck H, Nuyens D, et al. (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28: 131–138.
13. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, et al. (2002) Increased cerebrospinal fluid VEGF/Ang-1/Ang-2 levels in patients with Alzheimer’s disease and vascular dementia. Neurobiol Aging 23: 1602–1612.
14. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253: 98–108.
15. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, et al. (2004) Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer’s disease. J Neuropathol Exp Neurol 63: 554–573.
16. Storkebaum E, Lambrechts D, Carmeliet P (2008) Neurovascular signalling in neurodegeneration. Nat Rev Neurosci 9: 169–181.
17. Lambrechts D, Poesen K, Fernandez-Santiago R, Al-Chalabi A, Del Bo R, et al. (2008) Upregulation of vascular endothelial growth factor expression in CSF from Behcet’s disease with neurological involvement. J Neurol Sci 266: 173–178.
18. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP (2009) VEGF genetic polymorphism is associated with increased risk of developing Alzheimer’s disease. J Cereb Blood Flow Metab 29: 149–150.
19. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, et al. (2010) Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133: 1602–1614.
20. Rosemijn JM, Krum JM (2004) New roles for VEGF in nervous tissue–beyond blood vessels. Exp Neurol 187: 246–253.
21. Zacchigna S, Lambrechts D, Carmeliet P (2008) Neurovascular signalling in neurodegeneration. Nat Rev Neurosci 9: 169–181.
22. Tham E, Gielen AW, Khademi M, Wallstrom E, et al. (2007) Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 39: 1108–1113.
23. Pons CJ, Rett DW, Schmeling L, McDonal DW, Davis FA, et al. (1985) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227–231.
24. Gonzalez JR, Fotheringham EV, Chua K, Martin CJ, et al. (2007) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34: 383–394.
25. Teunissen CE, Iacobaeus E, Khadem M, Brundin L, Norenberg M, et al. (2009) Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 72: 1322–1329.
26. Landmark F, Dusek F, Iacobaeus E, Kockum I, Wallstrom E, et al. (2007) Vascular endothelial growth factor is associated with multiple sclerosis. J Neurol 254: 1059–1064.
27. Pozzi AM, Battaglia A, Schenk C, et al. (2009) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34: 383–394.